The proteasome inhibitor MG132 potentiates TRAIL receptor agonist-induced apoptosis by stabilizing tBid and Bik in human head and neck squamous cell carcinoma cells

Experimental Cell Research

Volumn 318, Issue 13, 2012, Pages 1564-1576

  Sung, Eun Sil ^a   Park, Kyung Jin ^a   Choi, Hye Ji ^a   Kim, Chul Ho ^b   Kim, Yong Sung ^a  

^a Ajou University   (South Korea)

^b Ajou University School of Medicine   (South Korea)

Author keywords

Apoptosis; Bcl 2 protein family; HNSCC; Proteasome inhibitor; TRAIL receptors

Indexed keywords

ANTINEOPLASTIC AGENT; AY 4; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CASPASE 3; CASPASE 8; CASPASE 9; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN BID; PROTEIN MCL 1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CARCINOMA CELL; CONTROLLED STUDY; DRUG POTENTIATION; GENE SILENCING; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SQUAMOUS CELL CARCINOMA;

EID: 84862025394     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2012.04.003     Document Type: Article

References (44)

1. Leemans C.R., Braakhuis B.J., Brakenhoff R.H. The molecular biology of head and neck cancer. Nat. Rev. Cancer 2011, 11:9-22.
2. Lee J., Moon C. Current status of experimental therapeutics for head and neck cancer. Exp. Biol. Med. (Maywood) 2011, 236:375-389.
3. Elrod H.A., Fan S., Muller S., Chen G.Z., Pan L., Tighiouart M., Shin D.M., Khuri F.R., Sun S.Y. Analysis of death receptor 5 and caspase-8 expression in primary and metastatic head and neck squamous cell carcinoma and their prognostic impact. PLoS One 2010, 5:e12178.
4. Yoldas B., Ozer C., Ozen O., Canpolat T., Dogan I., Griffith T.S., Sanlioglu S., Ozluoglu L.N. Clinical significance of TRAIL and TRAIL receptors in patients with head and neck cancer. Head Neck 2011, 33:1278-1284.
5. Ashkenazi A. Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat. Rev. Drug Discov. 2008, 7:1001-1012.
6. Fox N.L., Humphreys R., Luster T.A., Klein J., Gallant G. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-1 and receptor-2 agonists for cancer therapy. Expert Opin. Biol. Ther. 2010, 10:1-18.
7. Mahmood Z., Shukla Y. Death receptors: targets for cancer therapy. Exp. Cell Res. 2010, 316:887-899.
8. Adams J.M., Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007, 26:1324-1337.
9. Ott M., Norberg E., Zhivotovsky B., Orrenius S. Mitochondrial targeting of tBid/Bax: a role for the TOM complex?. Cell Death Differ. 2009, 16:1075-1082.
10. Shamas-Din A., Brahmbhatt H., Leber B., Andrews D.W. BH3-only proteins: orchestrators of apoptosis. Biochim. Biophys. Acta 2011, 1813:508-520.
11. Seki N., Toh U., Sayers T.J., Fujii T., Miyagi M., Akagi Y., Kusukawa J., Kage M., Shirouzu K., Yamana H. Bortezomib sensitizes human esophageal squamous cell carcinoma cells to TRAIL-mediated apoptosis via activation of both extrinsic and intrinsic apoptosis pathways. Mol. Cancer Ther. 2010, 9:1842-1851.
12. Yoshiba S., Iwase M., Kurihara S., Uchida M., Kurihara Y., Watanabe H., Shintani S. Proteasome inhibitor sensitizes oral squamous cell carcinoma cells to TRAIL-mediated apoptosis. Oncol. Rep. 2011, 25:645-652.
13. Kim J.H., Ajaz M., Lokshin A., Lee Y.J. Role of antiapoptotic proteins in tumor necrosis factor-related apoptosis-inducing ligand and cisplatin-augmented apoptosis. Clin. Cancer Res. 2003, 9:3134-3141.
14. Yeh C.C., Deng Y.T., Sha D.Y., Hsiao M., Kuo M.Y. Suberoylanilide hydroxamic acid sensitizes human oral cancer cells to TRAIL-induced apoptosis through increase DR5 expression. Mol. Cancer Ther. 2009, 8:2718-2725.
15. Dhandapani L., Yue P., Ramalingam S.S., Khuri F.R., Sun S.Y. Retinoic acid enhances TRAIL-induced apoptosis in cancer cells by upregulating TRAIL receptor 1 expression. Cancer Res. 2011, 71:5245-5254.
16. Fennell D.A., Chacko A., Mutti L. BCL-2 family regulation by the 20S proteasome inhibitor bortezomib. Oncogene 2008, 27:1189-1197.
17. Zhu H., Zhang L., Dong F., Guo W., Wu S., Teraishi F., Davis J.J., Chiao P.J., Fang B. Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors. Oncogene 2005, 24:4993-4999.
18. Luster T.A., Carrell J.A., McCormick K., Sun D., Humphreys R. Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib. Mol. Cancer Ther. 2009, 8:292-302.
19. Naumann I., Kappler R., von Schweinitz D., Debatin K.M., Fulda S. Bortezomib primes neuroblastoma cells for TRAIL-induced apoptosis by linking the death receptor to the mitochondrial pathway. Clin. Cancer Res. 2011, 17:3204-3218.
20. Nikrad M., Johnson T., Puthalalath H., Coultas L., Adams J., Kraft A.S. The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim. Mol. Cancer Ther. 2005, 4:443-449.
21. Unterkircher T., Cristofanon S., Vellanki S.H., Nonnenmacher L., Karpel-Massler G., Wirtz C.R., Debatin K.M., Fulda S. Bortezomib primes glioblastoma, including glioblastoma stem cells, for TRAIL by increasing tBid stability and mitochondrial apoptosis. Clin. Cancer Res. 2011, 17:4019-4030.
22. Sung E.S., Kim A., Park J.S., Chung J., Kwon M.H., Kim Y.S. Histone deacetylase inhibitors synergistically potentiate death receptor 4-mediated apoptotic cell death of human T-cell acute lymphoblastic leukemia cells. Apoptosis 2010, 15:1256-1269.
23. Sung E.S., Park K.J., Lee S.H., Jang Y.S., Park S.K., Park Y.H., Kwag W.J., Kwon M.H., Kim Y.S. A novel agonistic antibody to human death receptor 4 induces apoptotic cell death in various tumor cells without cytotoxicity in hepatocytes. Mol. Cancer Ther. 2009, 8:2276-2285.
24. Kim S.Y., Chu K.C., Lee H.R., Lee K.S., Carey T.E. Establishment and characterization of nine new head and neck cancer cell lines. Acta Otolaryngol. 1997, 117:775-784.
25. Kang J.W., Kim J.H., Song K., Kim S.H., Yoon J.H., Kim K.S. Kaempferol and quercetin, components of Ginkgo biloba extract (EGb 761), induce caspase-3-dependent apoptosis in oral cavity cancer cells. Phytother. Res. 2010, 24(Suppl. 1):S77-S82.
26. Lee C.H., Park K.J., Sung E.S., Kim A., Choi J.D., Kim J.S., Kim S.H., Kwon M.H., Kim Y.S. Engineering of a human kringle domain into agonistic and antagonistic binding proteins functioning in vitro and in vivo. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:9567-9571.
27. Lee S.H., Park D.W., Sung E.S., Park H.R., Kim J.K., Kim Y.S. Humanization of an agonistic anti-death receptor 4 single chain variable fragment antibody and avidity-mediated enhancement of its cell death-inducing activity. Mol. Immunol. 2010, 47:816-824.
28. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 1984, 22:27-55.
29. Park K.J., Lee C.H., Kim A., Jeong K.J., Kim C.H., Kim Y.S. Death receptors 4 and 5 activate Nox1 NADPH oxidase through riboflavin kinase to induce reactive oxygen species-mediated apoptotic cell death. J. Biol. Chem. 2012, 287:3313-3325.
30. Hasegawa M., Kawase K., Inohara N., Imamura R., Yeh W.C., Kinoshita T., Suda T. Mechanism of ASC-mediated apoptosis: bid-dependent apoptosis in type II cells. Oncogene 2007, 26:1748-1756.
31. Duiker E.W., Meijer A., van der Bilt A.R., Meersma G.J., Kooi N., van der Zee A.G., de Vries E.G., de Jong S. Drug-induced caspase 8 upregulation sensitises cisplatin-resistant ovarian carcinoma cells to rhTRAIL-induced apoptosis. Br. J. Cancer 2011, 104:1278-1287.
32. Varin E., Denoyelle C., Brotin E., Meryet-Figuiere M., Giffard F., Abeilard E., Goux D., Gauduchon P., Icard P., Poulain L. Downregulation of Bcl-xL and Mcl-1 is sufficient to induce cell death in mesothelioma cells highly refractory to conventional chemotherapy. Carcinogenesis 2010, 31:984-993.
33. Werneburg N.W., Guicciardi M.E., Bronk S.F., Kaufmann S.H., Gores G.J. Tumor necrosis factor-related apoptosis-inducing ligand activates a lysosomal pathway of apoptosis that is regulated by Bcl-2 proteins. J. Biol. Chem. 2007, 282:28960-28970.
34. Breitschopf K., Zeiher A.M., Dimmeler S. Ubiquitin-mediated degradation of the proapoptotic active form of bid. A functional consequence on apoptosis induction. J. Biol. Chem. 2000, 275:21648-21652.
35. Lee C.H., Park K.J., Kim S.J., Kwon O., Jeong K.J., Kim A., Kim Y.S. Generation of bivalent and bispecific kringle single domains by loop grafting as potent agonists against death receptors 4 and 5. J. Mol. Biol. 2011, 411:201-219.
36. Li C., Li R., Grandis J.R., Johnson D.E. Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells. Mol. Cancer Ther. 2008, 7:1647-1655.
37. Fribley A.M., Evenchik B., Zeng Q., Park B.K., Guan J.Y., Zhang H., Hale T.J., Soengas M.S., Kaufman R.J., Wang C.Y. Proteasome inhibitor PS-341 induces apoptosis in cisplatin-resistant squamous cell carcinoma cells by induction of Noxa. J. Biol. Chem. 2006, 281:31440-31447.
38. Willis S.N., Chen L., Dewson G., Wei A., Naik E., Fletcher J.I., Adams J.M., Huang D.C. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev. 2005, 19:1294-1305.
39. Shimazu T., Degenhardt K., Nur E.K.A., Zhang J., Yoshida T., Zhang Y., Mathew R., White E., Inouye M. NBK/BIK antagonizes MCL-1 and BCL-XL and activates BAK-mediated apoptosis in response to protein synthesis inhibition. Genes Dev. 2007, 21:929-941.
40. Trask D.K., Wolf G.T., Bradford C.R., Fisher S.G., Devaney K., Johnson M., Singleton T., Wicha M. Expression of Bcl-2 family proteins in advanced laryngeal squamous cell carcinoma: correlation with response to chemotherapy and organ preservation. Laryngoscope 2002, 112:638-644.
41. Sharma H., Sen S., Lo Muzio L., Mariggio A., Singh N. Antisense-mediated downregulation of anti-apoptotic proteins induces apoptosis and sensitizes head and neck squamous cell carcinoma cells to chemotherapy. Cancer Biol. Ther. 2005, 4:720-727.
42. Nencioni A., Hua F., Dillon C.P., Yokoo R., Scheiermann C., Cardone M.H., Barbieri E., Rocco I., Garuti A., Wesselborg S., Belka C., Brossart P., Patrone F., Ballestrero A. Evidence for a protective role of Mcl-1 in proteasome inhibitor-induced apoptosis. Blood 2005, 105:3255-3262.
43. Kundu S.K., Nestor M. Targeted therapy in head and neck cancer. Tumour Biol. 2012, 10.1007/s13277-13012-10350-13272.
44. Dudek A.Z., Lesniewski-Kmak K., Shehadeh N.J., Pandey O.N., Franklin M., Kratzke R.A., Greeno E.W., Kumar P. Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor. Br. J. Cancer 2009, 100:1379-1384.